Vildagliptin treatment for type 2 diabetic patients in clinical practice
10.3760/cma.j.issn.1000-6699.2011.10.024
- VernacularTitle:维格列汀在2型糖尿病治疗中的应用
- Author:
Wang JIAN
;
Chen YE
- Publication Type:Journal Article
- Keywords:
Vildagliptin;
Dipeptidyl peptidase-4;
Diabetes mellitus,type 2
- From:
Chinese Journal of Endocrinology and Metabolism
2011;27(10):873-876
- CountryChina
- Language:Chinese
-
Abstract:
Vildagliptin is a potent and specific inhibitor of dipeptidyl peptidase 4,which has been implicated to enhance and prolong the physiological actions of incretion hormones including glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.Vildagliptin is an orally administered drug and has been licensed for the treatment of type 2 diabetes mellitus.Vildagliptin monotherapy or in combination with other drugs can effectively lower glycosylated haemoglobin levels to a great extent.In addition,vildagliptin acts in a glucose-dependent manner,explaining its low risk of hypoglycemia.This drug has been proved well tolerated with few gastrointestinal side effects or oedema.Therefore vildagliptin is a promising new option for type 2 diabetic patients,and these patients would achieve better glycemic control and fewer complications in the long run.
